Julian Adams, PhD, the president of research and development at Infinity Pharmaceuticals, describes the mechanism of action for the experimental PI3 kinase delta/gamma inhibitor IPI-145 in hematologic malignancies.
PI3 kinase, specifically the delta and gamma isoforms, are expressed ubiquitously on cells associated with the immune system, specifically B cells, T cells, and cells of myeloid origin. In general, Adams notes, PI3 kinase is the master regulator of cellular activation, proliferation, survival, and intracellular trafficking. It is utilized by hematologic malignancies for trafficking into the lymph cells, where the cancer survives.
Inhibiting PI3 kinase delta/gamma forces the cancer cells out of the lymph node microenvironment, Adams suggests. Once blocked from the lymph cells, the cancer is restricted to the peripheral blood, where it dies.
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia